Get our Free Drug Patent Expiration Updates

Serving hundreds of leading biopharmaceutical companies globally:

Chinese Patent Office
US Department of Justice
Fish and Richardson
Boehringer Ingelheim
Farmers Insurance
Dow
Julphar
US Army
Covington

Generated: October 23, 2018

DrugPatentWatch Database Preview

ABBVIE Company Profile

« Back to Dashboard

What is the competitive landscape for ABBVIE, and what generic alternatives to ABBVIE drugs are available?

ABBVIE has ninety approved drugs.

There are eighty-nine US patents protecting ABBVIE drugs.

Summary for ABBVIE
US Patents:89
Tradenames:78
Ingredients:65
NDAs:90
Drug Master File Entries: 1
Patent Litigation for ABBVIE: See patent lawsuits for ABBVIE

Drugs and US Patents for ABBVIE

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Abbvie K-TAB potassium chloride TABLET, EXTENDED RELEASE;ORAL 018279-003 Nov 25, 2013 AB2 RX Yes Yes ➤ Sign Up ➤ Sign Up
Abbvie Inc TRICOR fenofibrate TABLET;ORAL 021203-003 Sep 4, 2001 DISCN Yes No 6,277,405 ➤ Sign Up ➤ Sign Up
Abbvie Inc TRICOR fenofibrate TABLET;ORAL 021203-001 Sep 4, 2001 DISCN Yes No 7,037,529 ➤ Sign Up Y ➤ Sign Up
Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration

This preview shows a limited data set.
Subscribe to access the full database, or try a Free Trial

Expired US Patents for ABBVIE

Applicant Tradename Generic Name Dosage NDA Approval Date Patent No. Patent Expiration
Abbvie MAVIK trandolapril TABLET;ORAL 020528-002 Apr 26, 1996 4,933,361 ➤ Sign Up
Abbvie Endocrine Inc LUPRON DEPOT-PED leuprolide acetate INJECTABLE;INJECTION 020263-006 Jan 21, 1994 4,954,298 ➤ Sign Up
Abbvie DEPAKOTE divalproex sodium TABLET, DELAYED RELEASE;ORAL 018723-003 Oct 26, 1984 5,212,326*PED ➤ Sign Up
Applicant Tradename Generic Name Dosage NDA Approval Date Patent No. Patent Expiration

This preview shows a limited data set.
Subscribe to access the full database, or try a Free Trial

Paragraph IV (Patent) Challenges for ABBVIE drugs
Drugname Dosage Strength Tradename Submissiondate
➤ Subscribe Extended-release Tablets 4 mg/ 240 mg ➤ Subscribe 2007-07-24
➤ Subscribe Tablets 100 mg ➤ Subscribe 2010-12-21
➤ Subscribe Tablets 400 mg and 600 mg ➤ Subscribe 2010-05-10
➤ Subscribe Injection 0.002 mg per mL in 1 mL vial and 0.005 mg per mL in 1 mL and 2 mL vials ➤ Subscribe 2008-11-28
➤ Subscribe Tablets 145 mg ➤ Subscribe 2007-10-19
➤ Subscribe Capsules 4 mcg ➤ Subscribe 2008-08-25
➤ Subscribe Tablets 5 mg/200 mg ➤ Subscribe 2005-05-27
➤ Subscribe Gel 1.62% ➤ Subscribe 2012-04-06
➤ Subscribe Injection 2 mg/mL, 5 mL vial and 10 mg/mL, 20 mL vial ➤ Subscribe 2009-08-04
➤ Subscribe Extended-release Tablet 500 mg ➤ Subscribe 2010-12-06
➤ Subscribe Extended-release Tablets 500 mg ➤ Subscribe 2005-02-08
➤ Subscribe Delayed-release Capsules 135 mg ➤ Subscribe 2009-09-01
➤ Subscribe Extended-release Tablets 1 mg/240 mg ➤ Subscribe 2008-02-20
➤ Subscribe Oral Solution 80 mg/20 mg per mL ➤ Subscribe 2014-06-19
➤ Subscribe Tablets 1 mg, 2 mg and 4 mg ➤ Subscribe 2004-10-04
➤ Subscribe Capsules 100 mg ➤ Subscribe 2012-10-31
➤ Subscribe Tablets 48 mg ➤ Subscribe 2008-07-01
➤ Subscribe Capsules 1 mcg and 2 mcg ➤ Subscribe 2008-10-14
➤ Subscribe Tablets 2.5 mg/200 mg ➤ Subscribe 2006-02-24
➤ Subscribe Gel Metered-dose Pump 1% ➤ Subscribe 2008-12-19
➤ Subscribe Gel 1.62% (1.25 g and 2.5 g packets) ➤ Subscribe 2013-06-19
➤ Subscribe Injection 2 mg/mL, 10 mL vial ➤ Subscribe 2009-08-12
➤ Subscribe Extended-release Tablets 250 mg ➤ Subscribe 2004-05-03
➤ Subscribe Delayed-release Capsules 45 mg ➤ Subscribe 2009-09-02
➤ Subscribe Extended-release Tablets 2 mg/180 mg and 2 mg/240 mg ➤ Subscribe 2007-11-09
➤ Subscribe Tablets 100 mg/25 mg ➤ Subscribe 2008-12-23

Supplementary Protection Certificates for ABBVIE Drugs

Supplementary Protection Certificate SPC Country SPC Expiration SPC Description
0150015 00143 Estonia ➤ Sign Up PRODUCT NAME: DASABUVIIR;REG NO/DATE: EU/1/14/983 19.01.2015
C/GB07/011 United Kingdom ➤ Sign Up PRODUCT NAME: GADOFOSVESET TRISODIUM; REGISTERED: UK EU/1/05/313/001 20051003; UK EU/1/05/313/002 20051003; UK EU/1/05/313/003 20051003; UK EU/1/05/313/004 20051003; UK EU/1/05/313/005 20051003; UK EU/1/05/313/006 20051003; UK EU/1/05/313/007 20051003; UK EU/1/05/313/008 20051003; UK EU/1/05/313/009 20051003
2203431/01 Switzerland ➤ Sign Up BEI DER ANMELDUNG WURDE DER INHABER IRRTUEMLICH DOPPELT ERFASST.
Supplementary Protection Certificate SPC Country SPC Expiration SPC Description

This preview shows a limited data set.
Subscribe to access the full database, or try a Free Trial

Similar Applicant Names
Applicants may be listed under multiple names.
Here is a list of applicants with similar names.

For more information try a trial or see the plans and pricing

Serving hundreds of leading biopharmaceutical companies globally:

Cerilliant
Merck
Fish and Richardson
AstraZeneca
Julphar
US Department of Justice
Covington
Boehringer Ingelheim
UBS

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.